Evotec SE Stock price

Equities

EVT

DE0005664809

Biotechnology & Medical Research

Market Closed - Xetra 12:35:12 2024-03-28 pm EDT After market 03:26:11 pm
14.47 EUR +0.66% Intraday chart for Evotec SE 14.69 +1.54%
Sales 2023 * 781M 842M Sales 2024 * 918M 990M Capitalization 2.55B 2.75B
Net income 2023 * -54M -58.23M Net income 2024 * 53M 57.15M EV / Sales 2023 * 3.21 x
Net cash position 2023 * 46.3M 49.93M Net cash position 2024 * 37M 39.9M EV / Sales 2024 * 2.74 x
P/E ratio 2023 *
-46.6 x
P/E ratio 2024 *
63.6 x
Employees 5,086
Yield 2023 *
-
Yield 2024 *
-
Free-Float 90.65%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Evotec SE

1 day-0.66%
1 week+6.78%
Current month+4.55%
1 month+2.59%
3 months-33.71%
6 months-22.77%
Current year-32.99%
More quotes
1 week
13.30
Extreme 13.295
14.50
1 month
12.62
Extreme 12.615
14.50
Current year
12.62
Extreme 12.615
21.42
1 year
12.62
Extreme 12.615
24.44
3 years
12.62
Extreme 12.615
45.83
5 years
12.62
Extreme 12.615
45.83
10 years
2.42
Extreme 2.42
45.83
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 19-06-18
Director of Finance/CFO 51 23-02-06
Chief Operating Officer 54 12-04-30
Members of the board TitleAgeSince
Chief Executive Officer 61 19-06-18
Director/Board Member 56 19-06-18
Chairman 63 14-06-16
More insiders
Date Price Change Volume
24-03-28 14.47 +0.66% 796 897
24-03-27 14.38 +4.39% 714,193
24-03-26 13.77 +2.15% 521,063
24-03-25 13.48 -1.06% 331,860
24-03-22 13.62 +2.02% 508,208

Delayed Quote Xetra, March 28, 2024 at 06:19 am EDT

More quotes
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women's health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
14.38 EUR
Average target price
23 EUR
Spread / Average Target
+60.00%
Consensus
  1. Stock
  2. Equities
  3. Stock Evotec SE - Xetra